Shilpa Medicare CDMO pipeline reaches regulatory review

Shilpa Medicare Limited’s contract development and manufacturing organisation (CDMO) pipeline has reached commercial supply and regulatory-review stages, with 25+ active small-molecule programmes, four under registration and one commercialised in fiscal year 2026 (FY26), while Unicycive’s Oxylanthanum Carbonate has a United States Food and Drug Administration (US FDA) target action date of March 25, 2027.

What stage is Shilpa Medicare’s CDMO pipeline at?

Shilpa Medicare’s disclosed CDMO portfolio includes 25+ active small-molecule programmes and 5+ active large-molecule, or biologics, programmes. Within small molecules, one programme was commercialised in FY26 and is moving into long-term commercial supply, while four programmes are under registration with global regulators. Management expects approvals for those four programmes over the next 18 to 24 months.

The small-molecule portfolio also includes two late clinical-stage programmes: one completed Phase III and one entered Phase III. In biologics, Shilpa Medicare is supplying Phase I clinical material for three CDMO programmes, while three additional programmes are preparing to enter Phase I studies in FY28. The disclosed mix is therefore larger in small molecules than biologics, at 25+ versus 5+ active programmes, although both segments include clinical-supply activity.

Shilpa Medicare also reports work with five Big Pharma companies across small and large molecules. Management describes request-for-quotation (RFQ) flow as encouraging across both segments, but does not quantify the number, value or conversion rate of RFQs. That makes the four registration-stage programmes and the single FY26 commercialised programme the specifically quantified near-term markers.

How does the Unicycive OLC programme fit Shilpa Medicare’s pipeline?

Shilpa Medicare is the exclusive CDMO partner for Unicycive Therapeutics Inc’s Oxylanthanum Carbonate (OLC), covering active pharmaceutical ingredient (API) and formulation development under a comprehensive contract. OLC is being developed for hyperphosphatemia through the FDA’s 505(b)(2) regulatory pathway, and Shilpa Medicare says its milestone income spans product filing, approval and launch stages.

Unicycive resubmitted its new drug application (NDA), including chemistry, manufacturing and controls (CMC) data from a new drug-product manufacturing vendor. The US FDA set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027. Shilpa Medicare has commissioned a dedicated OLC block for drug substance, while manufacturing of drug-product supply remained under discussion in the presentation.

The next commercial step is therefore conditional on US FDA approval. Shilpa Medicare’s roadmap says commercialisation is expected after approval and again identifies the company as exclusive CDMO partner. The presentation describes OLC as potentially best-in-class and cites lanthanum-like phosphate-binding capacity, fewer and smaller pills, and a swallowed-whole format, but these remain part of Unicycive’s development case rather than claims for an approved product.

What capabilities does Shilpa Medicare say support CDMO projects?

Shilpa Medicare says it provides development and manufacturing from early discovery through custom synthesis, scale-up and clinical materials, alongside integrated delivery of drug substance and drug product. Its presentation calls this a clone-to-vial model and identifies fermentation, antibody-drug conjugates and glucagon-like peptide-1 (GLP-1) programmes as connected technology areas.

In its peer comparison, Shilpa Medicare rates itself very strong in small molecules, monoclonal antibodies and recombinant technology, fermentation, and manufacturing. It rates peptide, antibody-drug-conjugate and development capabilities as strong. These are Shilpa Medicare’s own assessments against three unnamed Indian peers and three unnamed global peers, rather than independently measured operating metrics.

The comparison presents Shilpa Medicare as combining biologics and small-molecule work across several categories. For example, it rates itself very strong in fermentation and monoclonal antibodies and recombinant technology, while at least one Indian or global peer is assigned negligible capability in each category. Shilpa Medicare also says it is among the few Indian CDMOs with integrated biologics and integrated antibody-drug-conjugate offerings, without giving a count of comparable companies.

Which milestones could expand Shilpa Medicare’s CDMO supply work?

The most specifically dated disclosed milestone is the March 25, 2027 PDUFA target action date for Unicycive’s OLC NDA. Shilpa Medicare has commissioned a dedicated commercial drug-substance block for OLC, but drug-product supply manufacturing was still under discussion. The date is a regulatory target action date, not confirmation of approval or a commercial launch.

Beyond OLC, management expects approvals for four small-molecule registration programmes within 18 to 24 months. The portfolio also has one Phase III programme completed and one that entered Phase III, while the biologics business is supplying three Phase I programmes and preparing three more for Phase I in FY28. The presentation gives no revenue forecast for individual projects.

Shilpa Medicare’s broader product roadmap separately lists OLC as an exclusive CDMO programme with commercialisation expected after US FDA approval. It also says dedicated peptide capacity is under way for semaglutide API and formulation work, with an FY28-FY29 horizon. Those semaglutide activities are not presented as additional programme counts within the 25+ small-molecule and 5+ biologics CDMO totals.

Conclusion

Shilpa Medicare’s disclosures show a CDMO portfolio at several stages of maturity: one small-molecule programme entered commercial supply in FY26, four are under regulatory registration, and other programmes are in Phase III or Phase I across small molecules and biologics. OLC is the most clearly dated opportunity because Shilpa Medicare holds exclusive CDMO status, has commissioned a drug-substance block and faces a March 25, 2027 US FDA action date.

The next items to watch are the US FDA decision on OLC, the unresolved discussion over drug-product supply manufacturing, and management’s expectation of approvals for four registration-stage programmes within 18 to 24 months. For biologics, preparation of three additional programmes for Phase I studies in FY28 is the next stated pipeline milestone.